LumiraDx is a point of care diagnostic company. Co.'s existing test menu includes its International Normalized Ratio test for monitoring warfarin therapy, its Glycated Hemoglobin test for monitoring diabetes, its NT-proBNP test for aiding in the diagnosis of heart failure, its D-Dimer test for aiding in diagnosis and exclusion of venous thromboembolism, and its C-Reactive Protein test which measures a universal biomarker of infection and inflammation. Co. has developed four rapid COVID-19 molecular reagent testing kits for use on open molecular systems, SARS-CoV-2 RNA STAR, SARS-CoV-2 RNA STAR Complete, SARS-CoV-2 & Flu A/B RNA STAR Complete and Dual-Target SARS CoV-2 STAR Complete. The LMDX average annual return since 2021 is shown above.
The Average Annual Return on the LMDX average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether LMDX average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the LMDX average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|